Pet Microbiome Diagnostics Market Forecasts to 2034 - Global Analysis By Product (Testing Kits, Instruments and Software and Services), Sample Type, Animal Type, Technology, Application, End User and By Geography

According to Stratistics MRC, the Global Pet Microbiome Diagnostics Market is accounted for $0.5 billion in 2026 and is expected to reach $1.6 billion by 2034 growing at a CAGR of 15.6% during the forecast period. Pet Microbiome Diagnostics refers to the analysis and assessment of microbial communities residing in the digestive system, skin, oral cavity, and other biological environments of companion animals using advanced genomic and molecular diagnostic technologies. These diagnostics evaluate the composition, diversity, and functional activity of beneficial and harmful microorganisms to identify imbalances associated with health conditions. Pet microbiome diagnostics support disease detection, nutritional optimization, preventive healthcare, personalized treatment planning, and overall wellness management in pets.

Market Dynamics:

Driver:

Gut health science advances

Rapid expansion of the scientific evidence base connecting companion animal gut microbiome composition to systemic health outcomes across gastrointestinal, immune, dermatological, and behavioral domains is creating growing clinical and consumer demand for diagnostic characterization. Peer-reviewed research demonstrating correlations between specific microbial signatures and conditions including inflammatory bowel disease, food sensitivity, and atopic dermatitis is strengthening veterinary confidence in microbiome diagnostic utility. Probiotic and prebiotic product manufacturers are commissioning microbiome diagnostic testing to validate product efficacy claims and support personalized recommendation platforms.

Restraint:

Lack of veterinary reference standards

The absence of validated reference ranges for healthy companion animal microbiome composition across breeds, ages, and geographic regions significantly limits clinical interpretability of microbiome diagnostic results. Without standardized normative databases, veterinarians cannot reliably distinguish pathological dysbiosis from normal microbial variation, reducing diagnostic confidence and clinical adoption rates. Methodological inconsistencies between sequencing platforms, bioinformatics pipelines, and sample handling protocols prevent meaningful result comparison across testing providers.

Opportunity:

Personalized nutrition applications

The convergence of companion animal microbiome diagnostics with personalized nutrition represents a high-growth commercial opportunity for testing companies, pet food manufacturers, and probiotic supplement developers. Microbiome profiles that inform customized dietary recommendations and probiotic strain selection create value-added service platforms that extend beyond one-time diagnostic sales into subscription nutrition programs. Direct-to-consumer testing kits linked to proprietary nutrition platforms capture recurring revenue through personalized supplement and food recommendation fulfillment. Partnership models between microbiome diagnostic companies and premium pet food manufacturers enable co-branded nutrition optimization services.

Threat:

Interpretation complexity limitations

The inherent complexity of microbiome data interpretation, including high inter-individual variability, site-specific microbial communities, and dynamic compositional responses to diet and environment, poses significant challenges for translating sequencing results into clinically actionable recommendations. Consumer-facing microbiome reports risk oversimplifying complex microbial ecology into misleading health narratives, potentially prompting inappropriate self-treatment or dietary interventions. Veterinarians may distrust consumer microbiome diagnostic platforms that report outside established clinical standards. The regulatory risk of microbiome tests that imply diagnostic or prognostic claims without adequate clinical validation creates legal exposure for testing companies.

Covid-19 Impact:

The COVID-19 pandemic disrupted companion animal microbiome diagnostics through laboratory operational restrictions and sequencing supply chain interruptions that delayed sample processing timelines. The pandemic concurrently elevated consumer interest in gut health science applied to both human and pet contexts, broadening public awareness of microbiome diagnostics. Accelerated pet adoption during lockdowns expanded the future addressable market. Post-pandemic, increased owner investment in preventive and personalized veterinary care has sustained demand momentum for companion animal microbiome testing and related nutritional optimization services.

The testing kits segment is expected to be the largest during the forecast period

The testing kits segment is expected to account for the largest market share during the forecast period, due to their convenience, accessibility, and growing adoption among pet owners and veterinary professionals. These kits enable efficient collection and submission of biological samples for microbiome analysis, supporting routine health assessments and preventive care initiatives. Rising awareness regarding the role of the microbiome in pet health, coupled with increasing demand for at-home diagnostic solutions, is strengthening market penetration. Continuous product innovation and expanding distribution networks further contribute to the segment's dominant position.

The shotgun metagenomic sequencing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the shotgun metagenomic sequencing segment is predicted to witness the highest growth rate, driven by its ability to provide comprehensive profiling of microbial communities without requiring prior target selection. This technology enables detailed identification of bacteria, viruses, fungi, and other microorganisms, supporting advanced diagnostics and personalized pet healthcare. Growing demand for precision veterinary medicine, increasing research on pet gut health, and advancements in next-generation sequencing platforms are further accelerating adoption. Its superior analytical capabilities continue to expand applications across microbiome-based disease assessment and wellness monitoring.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to its advanced veterinary diagnostics infrastructure, high companion animal ownership rates, and strong consumer and professional awareness of microbiome science in animal health contexts. The United States hosts the majority of commercial companion animal microbiome testing companies, including AnimalBiome, and leading research institutions with active companion animal microbiome reference database programs. Established veterinary diagnostic laboratory networks provide professional distribution channels for microbiome testing services. Consumer science literacy and premium pet health spending patterns support direct-to-consumer microbiome testing adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding companion animal ownership, increasing veterinary diagnostic investment, and growing awareness of gut microbiome science in pet health management across Japan, South Korea, China, and Australia. Local biotechnology companies in China and South Korea are developing cost-competitive companion animal microbiome testing platforms for domestic and regional distribution. Academic research institutions in Japan and Australia maintain active companion animal microbiome study programs, generating reference data that supports clinical test development.

Key players in the market

Some of the key players in Pet Microbiome Diagnostics Market include AnimalBiome, Inc., ThorneVet, Microbiome Labs, IDEXX Laboratories, Inc., Zoetis Inc., Nestle Purina PetCare Company, Mars, Incorporated, Hill's Pet Nutrition, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Eurofins Scientific SE, Neogen Corporation, NomNomNow Inc., Oligo Basics USA LLC, Biome9 and GlycanAge.

Key Developments:

In May 2026, AnimalBiome, Inc. launched an expanded canine and feline gut microbiome test panel incorporating shotgun metagenomic sequencing, providing breed-adjusted microbial diversity scores and personalized probiotic strain recommendations through an updated clinical reporting platform.

In April 2026, NomNomNow Inc. introduced a subscription-based microbiome monitoring program pairing quarterly fecal microbiome sequencing with dynamically adjusted fresh pet food formulations, targeting dogs with chronic gastrointestinal and dermatological conditions.

In March 2026, Eurofins Scientific SE expanded its veterinary diagnostic laboratory microbiome testing services to include equine gut microbiome profiling across seven European markets, supporting performance nutrition optimization programs for competitive sport horses.

Products Covered:

• Testing Kits
• Instruments
• Software and Services

Sample Types Covered:

• Fecal Samples
• Saliva Samples
• Skin Swab Samples
• Ear Swab Samples

Animal Types Covered:

• Dogs
• Cats
• Horses
• Other Companion Animals

Technologies Covered:

• 16S rRNA Sequencing
• Shotgun Metagenomic Sequencing
• Metabolomics
• qPCR
• Metatranscriptomics

Applications Covered:

• Gastrointestinal Health
• Dermatology
• Nutritional Assessment
• Obesity Management
• Immune System Health
• Behavioral Health Correlation

End Users Covered:

• Veterinary Hospitals and Clinics
• Diagnostic Laboratories
• Research Institutes
• Pet Owners
• Pet Food and Supplement Companies

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances